target menu
 

Jenster Publications

Publications

  • Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. Nat Rev Urol. 2017 May;14(5):312-322.
  • Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol. 2017 Apr;71(4):680-687.
  • Alves IT, Cano D, Böttcher R, van der Korput H, Dinjens W, Jenster G, Trapman J. A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer. Oncotarget. 2017 Jan 24;8(4):6043-6056.
  • Hoogstrate Y, Zhang C, Senf A, Bijlard J, Hiltemann S, van Enckevort D, Repo S, Heringa J, Jenster G, J A Fijneman R, Boiten JW, A Meijer G, Stubbs A, Rambla J, Spalding D, Abeln S. Integration of EGA secure data access into Galaxy.F1000Res. 2016 Dec 12;5. pii: ELIXIR-2841
  • Böttcher R, Dulla K, van Strijp D, Dits N, Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G, Hoffmann R. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. Oncotarget. 2016 Oct 25;7(43):70669-70684.
  • Utomo WK, Janmaat VT, Verhaar AP, Cros J, Lévy P, Ruszniewski P, den Berg MS, Jenster G, Bruno MJ, Braat H, Fuhler GM, Peppelenbosch MP. DNA integrity as biomarker in pancreatic cyst fluid. Am J Cancer Res. 2016 Aug 1;6(8):1837-41.
  • " Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G. Extracellular Vesicles and Their Role in Urologic Malignancies. Eur Urol. 2016 Aug;70(2):323-31.
  • Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol. 2016 Aug;70(2):312-22.
  • Hoogland AM, Böttcher R, Verhoef E, Jenster G, van Leenders GJ. Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget. 2016 Jun 21;7(25):37846-37856.
  • Aakula A, Kohonen P, Leivonen SK, Mäkelä R, Hintsanen P, Mpindi JP, Martens-Uzunova E, Aittokallio T, Jenster G, Perälä M, Kallioniemi O, Östling P.  Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. Eur Urol. 2016 Jun;69(6):1120-8.
  • Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders GJ, Jenster G, Bergman AM, Zwart W. mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. Oncotarget. 2016 May 31;7(22):32916-24.
  • Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova ES. A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget. 2016 Apr 26;7(17):24766-77.
  • Salih M, Fenton RA, Knipscheer J, Janssen JW, Vredenbregt-van den Berg MS, Jenster G, Zietse R, Hoorn EJ. An immunoassay for urinary extracellular vesicles. Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F796-F801.
  • Hoogstrate Y, Böttcher R, Hiltemann S, van der Spek PJ, Jenster G, Stubbs AP. FuMa: reporting overlap in RNA-seq detected fusion genes. Bioinformatics. 2016 Apr 15;32(8):1226-8.
  • Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Queiroz KC, Peppelenbosch MP, Stubbs AP, Pelizzaro-Rocha K, van Leenders GJ, Jenster G, Aoyama H, Ferreira CV, Fuhler GM. Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential. Eur Urol. 2016 Apr;69(4):710-9.
  • Duijvesz D, Versluis CY, van der Fels CA, Vredenbregt-van den Berg MS, Leivo J, Peltola MT, Bangma CH, Pettersson KS, Jenster G. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int J Cancer. 2015 Dec 15;137(12):2869-78.
  • Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015 Dec;68(6):939-45.
  • Böttcher R, Henderson DJ, Dulla K, van Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders GJ, Baillie GS, Jenster G, Houslay MD, Hoffmann R. Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression. Br J Cancer. 2015 Nov 17;113(10):1502-11.
  • Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, Wessels LF, Bergman AM, Zwart W. Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol Med. 2015 Nov;7(11):1450-64.
  • Hiltemann S, Jenster G, Trapman J, van der Spek P, Stubbs A. Discriminating somatic and germline mutations in tumor DNA samples without matching normals. Genome Res. 2015 Sep;25(9):1382-90.
  • Martens-Uzunova ES, Hoogstrate Y, Kalsbeek A, Pigmans B, Vredenbregt-van den Berg M, Dits N, Nielsen SJ, Baker A, Visakorpi T, Bangma C, Jenster G. C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer. Oncotarget. 2015 Jul 10;6(19):17430-44.
  • Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, Nykter M, Visakorpi T. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. Prostate. 2015 Jun;75(8):798-805.
  • Hoogstrate Y, Jenster G, Martens-Uzunova ES. FlaiMapper: computational annotation of small ncRNA-derived fragments using RNA-seq high-throughput data. Bioinformatics. 2015 Mar 1;31(5):665-73.
  • Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G. Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget. 2015 Feb 28;6(6):4036-50.
  • Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A. Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy. Int J Mol Sci. 2015 Feb 11;16(2):3856-69.   
  • Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G. Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget. 2015 Feb 28;6(6):4036-50.
  • Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, Nykter M, Visakorpi T. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. Prostate. 2015 Jun;75(8):798-805.
  • Martens-Uzunova ES, Hoogstrate Y, Kalsbeek A, Pigmans B, Vredenbregt-van den Berg M, Dits N, Nielsen SJ, Baker A, Visakorpi T, Bangma C, Jenster G. C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer. Oncotarget. 2015 Jul 10;6(19):17430-44.
  • Duijvesz D, Versluis CY, van der Fels CA, Vredenbregt-van den Berg MS, Leivo J, Peltola MT, Bangma CH, Pettersson KS, Jenster G. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int J Cancer. 2015 Dec 15;137(12):2869-78.
  • Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, Pelizzaro-Rocha K, van Leenders GJ, Jenster G, Aoyama H, Ferreira CV, Fuhler GM. Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential. Eur Urol. 2016 Apr;69(4):710-9.
  • Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S. Efficacy of Cabazitaxe in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015 Dec;68(6):939-45.
  • Hiltemann S, Jenster G, Trapman J, van der Spek P, Stubbs A. Discriminating somatic and germline mutations in tumor DNA samples without matching normals. Genome Res. 2015 Sep;25(9):1382-90.
  • Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, Wessels LF, Bergman AM, Zwart W. Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol Med. 2015 Sep 27;7(11):1450-64.
  • Aakula A, Kohonen P, Leivonen SK, Mäkelä R, Hintsanen P, Mpindi JP, Martens-Uzunova E, Aittokallio T, Jenster G, Perälä M, Kallioniemi O, Östling P.  Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. Eur Urol. 2015 Oct 20. pii: S0302-2838(15)00927-6.
  • Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ. Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:93-114.
  • Böttcher R, Henderson DJ, Dulla K, van Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders GJ, Baillie GS, Jenster G, Houslay MD, Hoffmann R. Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression. Br J Cancer. 2015 Nov 17;113(10):1502-11.
  • Hoogstrate Y, Böttcher R, Hiltemann S, van der Spek PJ, Jenster G, Stubbs AP. FuMa: reporting overlap in RNA-seq detected fusion genes. Bioinformatics. 2015 Dec 10. pii: btv721.
  • Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol. 2016 Jan 21. pii: S0302-2838(16)00012-9.
  • Salih M, Fenton RA, Knipscheer J, Janssen JW, Vredenbregt-van den Berg MS, Jenster G, Zietse R, Hoorn EJ. An Immunoassay for Urinary Extracellular Vesicles. Am J Physiol Renal Physiol. 2016 Jan 28:ajprenal.00463.2015.
  • Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G. Extracellular Vesicles and Their Role in Urologic Malignancies. Eur Urol. 2016 Feb 25. pii: S0302-2838(16)00224-4.
  • Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova E. A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget. 2016 Mar 23.
  • Drayton RM, Rehman I, Clarke R, Zhao Z, Pang K, Miah S, Stoehr R, Hartmann A, Blizard S, Lavin M, Bryant HE, Martens-Uzunova ES, Jenster G, Hamdy FC, Gardiner  RA, Catto JW. Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):268-75.
  • Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska E, Danen E. SYK is a candidate kinase target for the treatment of advanced prostate cancer. Cancer Res. 2015 Jan 1;75(1):230-40.
  • Hoogstrate Y, Jenster G, Martens-Uzunova ES. FlaiMapper: computational annotation of small ncRNA-derived fragments using RNA-seq high-throughput data. Bioinformatics. 2015 Mar 1;31(5):665-73
  • Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G. Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget. 2015 Feb 28;6(6):4036-50.
  • Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A. Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy. Int J Mol Sci. 2015 Feb 11;16(2):3856-69.
  • Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, Nykter M, Visakorpi T. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. Prostate. 2015 Mar 1.
  • Hiltemann S, Hoogstrate Y, der Spek Pv, Jenster G, Stubbs A. iReport: a generalised Galaxy solution for integrated experimental reporting. Gigascience. 2014 Oct 13;3:19.
  • Rodríguez-Blanco G, Burgers PC, Dekker LJ, Vredenbregt-van den Berg MS, Ijzermans JN, Schenk-Braat EA, Jenster G, Luider TM. Serum kynurenine/tryptophan ratio is not a potential marker for detecting prostate cancer. Clin Biochem. 2014 Sep;47(13-14):1347-8.
  • Henderson DJ, Byrne A, Dulla K, Jenster G, Hoffmann R, Baillie GS, Houslay MD. The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. Br J Cancer. 2014 Mar4;110(5):1278-87.
  • Teles Alves I, Hartjes T, McClellan E, Hiltemann S, Böttcher R, Dits N, Temanni MR, Janssen B, van Workum W, van der Spek P, Stubbs A, de Klein A, Eussen B, Trapman J, Jenster G. Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer. Oncogene. 2015 Jan 29;34(5):568-77.
  • Hiltemann S, Mei H, de Hollander M, Palli I, van der Spek P, Jenster G, Stubbs CGtag: complete genomics toolkit and annotation in a cloud-based Galaxy. Gigascience. 2014 Jan 24;3(1):1.
  • Rodríguez-Blanco G, Burgers PC, Dekker LJ, Ijzermans JJ, Wildhagen MF, Schenk-Braat EA, Bangma CH, Jenster G, Luider TM. Serum levels of arachidonic acid metabolites change during prostate cancer progression. Prostate. 2014 May;74(6):618-27.
  • Duijvesz D, Burnum-Johnson KE, Gritsenko MA, Hoogland AM, Vredenbregt-van den  Berg MS, Willemsen R, Luider T, Paša-Tolić L, Jenster G. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One. 2013 Dec 31;8(12):e82589.
  • Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G, van Leenders GJ. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease. Prostate.  2014 May;74(5):488-96. 
  • Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014 Jun;65(6):1140-51.
  • Iglesias-Gato D, Chuan YC, Wikström P, Augsten S, Jiang N, Niu Y, Seipel A, Danneman D, Vermeij M, Fernandez-Perez L, Jenster G, Egevad L, Norstedt G, Flores-Morales A. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis. 2014 Jan;35(1):24-33.
  • Kumagai J, Hofland J, Erkens-Schulze S, Dits NF, Steenbergen J, Jenster G, Homma Y, de Jong FH, van Weerden WM. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. Prostate. 2013 Nov;73(15):1636-50
  • Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A.  2013 Aug 6;110(32):13109-13
  • Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A. Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different? Int J Mol Sci. 2013 Jun 3;14(6):11816-29
  • Hiltemann S, McClellan EA, van Nijnatten J, Horsman S, Palli I, Teles Alves I, Hartjes T, Trapman J, van der Spek P, Jenster G, Stubbs A. iFUSE: integrated fusion gene explorer. Bioinformatics. 2013 Jul 1;29(13):1700-1.
  • Teles Alves I, Hiltemann S, Hartjes T, van der Spek P, Stubbs A, Trapman J, Jenster G. Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line. Hum Genet. 2013 Jun;132(6):709-13
  • Gasi Tandefelt D, Boormans JL, van der Korput HA, Jenster GW, Trapman J. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol. 2013 Dec;64(6):941-50
  • Martens-Uzunova ES, Olvedy M, Jenster G. Beyond microRNA--novel RNAs derived  from small non-coding RNA and their implication in cancer. Cancer Lett. 2013 Nov 1;340(2):201-11
  • Boormans JL, Korsten H, Ziel-van der Made AJ, van Leenders GJ, de Vos CV, Jenster G, Trapman J. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. Int J Cancer. 2013 Jul 15;133(2):335-45.
  • Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, Bond VC, Borràs  FE, Breakefield X, Budnik V, Buzas E, Camussi G, Clayton A, Cocucci E, Falcon-Perez JM, Gabrielsson S, Gho YS, Gupta D, Harsha HC, Hendrix A, Hill AF, Inal JM, Jenster G, Krämer-Albers EM, Lim SK, Llorente A, Lötvall J, Marcilla A,  Mincheva-Nilsson L, Nazarenko I, Nieuwland R, Nolte-'t Hoen EN, Pandey A, Patel T, Piper MG, Pluchino S, Prasad TS, Rajendran L, Raposo G, Record M, Reid GE, Sánchez-Madrid F, Schiffelers RM, Siljander P, Stensballe A, Stoorvogel W, Taylor D, Thery C, Valadi H, van Balkom BW, Vázquez J, Vidal M, Wauben MH, Yáñez-Mó M, Zoeller M, Mathivanan S. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012;10(12):e1001450.
  • Larne O, Martens-Uzunova E, Hagman Z, Edsjö A, Lippolis G, den Berg MS, Bjartell A, Jenster G, Ceder Y. miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int J Cancer. 2013 Jun 15;132(12):2867-75.
  • Hofland J, van Weerden WM, Steenbergen J, Dits NF, Jenster G, de Jong FH. Activin A stimulates AKR1C3 expression and growth in human prostate cancer. Endocrinology. 2012 Dec;153(12):5726-34
  • Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol. 2012 Aug 6. [Epub ahead of print]
  • Jansen F, van Rijswijk A, Teubel W, van Weerden W, Reneman S, van den Bemd GJ, Roobol M, Bangma CH, Staal F, Jenster G. Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers. J Proteome Res. 2012 Feb 3;11(2):728-35
  • Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2012 Mar;25(3):471-9
  • van de Wijngaart DJ, Dubbink HJ, van Royen ME, Trapman J, Jenster G. Androgen receptor coregulators: Recruitment via the coactivator binding groove. Mol Cell Endocrinol. 2012 Apr 16;352(1-2):57-69
  • van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W, Jenster G. Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer. PLoS One. 2011;6(11):e26753
  • Rijlaarsdam MA, van Herk HA, Gillis AJ, Stoop H, Jenster G, Martens J, van Leenders GJ, Dinjens W, Hoogland AM, Timmermans M, Looijenga LH. Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours. Br J Cancer. 2011 Sep 6;105(6):854-63
  • Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS One. 2011;6(8):e23144
  • Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012 Feb 23;31(8):978-91
  • Porkka KP, Ogg EL, Saramäki OR, Vessella RL, Pukkila H, Lähdesmäki H, van Weerden WM, Wolf M, Kallioniemi OP, Jenster G, Visakorpi T. The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer. 2011 Jul;50(7):499-509
  • Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol. 2011 May;59(5):823-31.
  • Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One. 2010 Oct 19;5(10):e13500.
  • Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T. Androgen regulation of micro-RNAs in prostate cancer. Prostate. 2011 May;71(6):604-14.
  • van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Jenster G, Trapman J. Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection. Prostate. 2011 Feb 15;71(3):241-53.
  • Dekker LJ, Burgers PC, Charif H, van Rijswijk AL, Titulaer M, Jenster G, Bischoff R, Bangma CH, Luider TM. Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Proteomics. 2010 Jun;10(12):2348-58.
  • Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res. 2009 Oct 15;15(20):6398-403.
  • van de Wijngaart DJ, Molier M, Lusher SJ, Hersmus R, Jenster G, Trapman J, Dubbink HJ. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J Biol Chem. 2010 Feb 12;285(7):5097-105.
  • Hofland J., van Weerden W.M., Dits N.F.J., Steenbergen J., van Leenders G.J.L.H., Jenster G., Schröder F.H., de Jong F.H. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.Cancer Res. 2010 Feb 1;70(3):1256-64.
  • van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Trapman J, Jenster G.  Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression. Mol Endocrinol. 2009 Nov;23(11):1776-86.
  • van der Heul-Nieuwenhuijsen L, Dits NF,  van IJcken W, de Lange D, Jenster G. The FOXF2 PathwayintheHuman Prostate Stroma. The Prostate 2009 Oct 1;69(14):1538-47.
  • Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. Eur Urol. 2009 Aug;56(2):275-86.
  • van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G.Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 2009 Jun;103(11):1574-80.
  • Jansen FH, Krijgsveld J, van Rijswijk A, van den Bemd GJ, van den Berg MS, van Weerden WM, Willemsen R, Dekker LJ, Luider TM, Jenster G. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics. 2009 Jun;8(6):1192-205.
  • Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol. 2009 Feb;23(2):213-25.
  • Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins. Eur Urol. 2009 Mar;55(3):563-74.
  • Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, Dits NF, Boormans JL, van der Kwast TH, van Dekken H, Bangma CH, Korsten H, Kraaij R, Jenster G, Trapman J.Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 2008 Sep 15;68(18):7541-9.
  • Jelier R, Schuemie MJ, Veldhoven A, Dorssers LC, Jenster G, Kors JA. Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol. 2008;9(6):R96.
  • Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008 May 1;68(9):3094-8.
  • Jelier R, Jenster G, Dorssers LC, Wouters BJ, Hendriksen PJ, Mons B, Delwel R, Kors JA. Text-derived concept profiles support assessment of DNA microarray data for acute myeloid leukemia and for androgen receptor stimulation. BMC Bioinformatics. 8:14 (2007)
  • Rompp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, Spengler B, Heeren R, Smitt PS, Luider TM. Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. Proteomics. 7(3):474-481 (2007)
  • Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66(22):10658-10663 (2006)
  • van der Heul-Nieuwenhuijsen L, Hendriksen PJ, van der Kwast TH, Jenster G. Gene expression profiling of the human prostate zones. BJU Int. 98(4):886-897 (2006)
  • van den Bemd GJ, Krijgsveld J, Luider TM, van Rijswijk AL, Demmers JA, Jenster G. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol Cell Proteomics. 5(10):1830-1839 (2006)
  • Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 66(10):5012-5020 (2006)
  • van de Wijngaart DJ, van Royen ME, Hersmus R, Pike AC, Houtsmuller AB, Jenster G, Trapman J, Dubbink HJ. Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. J Biol Chem. 281(28):19407-19416 (2006)
  • Dubbink HJ, Hersmus R, Pike AC, Molier M, Brinkmann AO, Jenster G, Trapman J. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping. Mol Endocrinol. 20(8):1742-1755 (2006)
  • Bangma C, Jenster G. Bladder carcinogenesis, in search of clues and genes. Eur Urol. 50:205-207 (2006)
  • Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, Jenster G. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur Urol. 49(2):245-57 (2006)
  • Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, van Weerden WM, Jenster G. Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int J Cancer. 117:221-229 (2005)
  • Veldhoven A, de Lange D, Smid M, de Jager V, Kors JA, Jenster G. Storing, linking, and mining microarray databases using SRS. BMC Bioinformatics. Jul 27;6(1):192 (2005)
  • Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Sillevis Smitt PA. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in breast cancer patients. Mol Cell Proteomics. 4(9):1341-1349 (2005)
  • Alako BT, Veldhoven A, van Baal S, Jelier R, Verhoeven S, Rullmann T, Polman J, Jenster G. CoPub Mapper: mining MEDLINE based on search term co-publication. BMC Bioinformatics. 6:51 (2005)
  • Dekker LJ, Dalebout JC, Siccama I, Jenster G, Sillevis Smitt PA, Luider TM. A new method to analyze matrix-assisted laser desorption/ionization time-of-flight peptide profiling mass spectra. Rapid Commun Mass Spectrom. 19:865-870 (2005)
  • Jelier R, Jenster G, Dorssers LC, van der Eijk CC, van Mulligen EM, Mons B, Kors JA. Co-occurrence based meta-analysis of scientific texts: retrieving biological relationships between genes. Bioinformatics. 21:2049-2058 (2005)
  • Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, Lanz RB, Zoumpourlis VC, Schwartz RJ. Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. J Biol Chem. 280:7786-7792 (2005)
  • D.Y. Lin, H.I. Fang, A.H. Ma, Y.S. Pu, G. Jenster, H.J. Kung, and H.M. Shih. Daxx, an androgen receptor binding protein that suppresses androgen response. Mol. Cell. Biol. 24:10529-10541 (2004)
  • GTG Chang, M Jhamai, WM van Weerden, G Jenster and AO Brinkmann. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer. Endocrine-Related Cancer. 11:815-822 (2004)
  • Benjamin CL, Jenster G, Piedrahita JA. Use of artificial androgen receptor coactivators to alter myoblast proliferation. J Steroid Biochem Mol Biol. 91:111-119 (2004)
  • G. Jenster. A visualzation concept of dynamic signaling networks. Molecular and Cellular Endocrinology. 218: 1-6 (2004)
  • Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3- is involved in the phosphorylation and suppression of androgen receptor activity. Journal of Biological Chemistry 279: 19191-19200 (2004).
  • Jelier R, Jenster G, Dorssers LC, Van Mulligen EM, Mons B, Kors JA. Mining microarray datasets aided by knowledge stored in literature. Proc AMIA Symp. (2003) 879.
  • M. Smid, L.C.J. Dorssers, and G. Jenster. Venn Mapping: Clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatics. 19:2065-2071 (2003).
  • Kniazev IuP, Cheburkin IuV, Spikermann K, Peter S, Jenster G, Bangma KH, Karelin MI, Shkol'nik MI, Urbanskii AI, Evtushenko VI, Ullrich A, Kniazev PG. Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma. Mol Biol (Mosk). 37:97-111 (2003). Russian.
  • Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W. AKT-Independent Protection of Prostate Cancer Cells from Apoptosis Mediated through Complex Formation between the Androgen Receptor and FKHR. Mol Cell Biol. 23:104-118 (2003).
  • K.S. Bramlett, N.F.J. Dits, X. Sui, M.C. Jorge, X. Zhu, and G. Jenster. Repression of androgen receptor-driven gene expression by dominant negative androgen receptors. Mol. Cell. Endocrinol. 183: 19-29 (2001).
  • D. Phan, X. Sui, W. Luo, S. Najjar, G. Jenster, and S-H. Lin. Androgen regulation of cell adhesion molecule-1 (C-CAM1) gene. Mol. Cell. Endocrinol. 184:115-123 (2001).
  • G. Jenster. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J. of  Pathology 191: 227-228 editorial (2000).
  • S. Lu, G. Jenster, and D.E. Epner. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor SP complex. Molecular Endocrinology 14: 753-760 (2000).
  • G. Jenster. The role of the androgen receptor in the development and progression of prostate cancer. Seminars in Oncology 26:407-421 (1999).
  • X Sui, K. Bramlett, M. Jorge, D.A. Swanson, A.C. von Eschenbach and G. Jenster. Specific androgen receptor activation by an artificial coactivator. J Biol. Chem. 274: 9449-9454 (1999).
  • T.E. Spencer, A.G. Stagg, M.M. Joyce, G. Jenster, C.G. Wood, F.W. Bazer, A.A. Wiley and F.F. Bartol. Discovery and characterization of endometrial epithelial messenger ribonucleic acids using the ovine uterine gland knockout model. Endocrinology 140: 4070-4080 (1999).
  • G. Jenster. Coactivators and corepressors as mediators of nuclear receptor function: an update. Molecular and Cellular Endocrinology, 143, 1-7 (1998)
  • G. Jenster, T.E. Spencer, M.M. Burcin, S.Y. Tsai, M-J. Tsai and B.W. O'Malley. Steroid receptor induction of gene transcription: a two-step model. Proc. Natl. Acad. Sci. USA 94: 7879-7884 (1997). First two authors made equal contributions.
  • T.E. Spencer, G. Jenster, M.M. Burcin, C.D. Allis, J. Zhou, S.Y., C.A. Mizzen, N.J. McKenna, S.A. Onate, S.Y. Tsai, M-J. Tsai and B.W. O'Malley. Steroid receptor coactivator one is a histone acetyltransferase. Nature 389: 194-198 (1997). First two authors made equal contributions
  • H. Shibata, T.E. Spencer, S.A. Onate, G. Jenster, S.Y. Tsai, M.-J. Tsai, B.W. O'Malley. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.. Recent Progress in Hormone Research, Vol. 52, pp 1-25 (1997).
  • A.O. Brinkmann, G. Jenster, C. Ris-Stalpers, J.A.G.M. van der Korput, H.T. Bruggenwirth, A.L.M. Boehmer and J. Trapman. Molecular basis of androgen insensitivity. . Steroids, 61: 172-175 (1996).
  • B. van Steensel, G. Jenster, K. Damm, A.O. Brinkmann and R. van Driel. Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. J. Cell Biochem. 57: 465-478 (1995). Both authors made equal contributions to the work described in this article.
  • Guido Jenster, Hetty A.G.M. van der Korput, Jan Trapman and Albert O. Brinkmann. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 270: 7341-7346 (1995).
  • A.O. Brinkmann, G. Jenster, C. Ris-Stalpers, J.A.G.M. van der Korput, H.T. Bruggenwirth, A.L.M. Boehmer and J. Trapman. Androgen receptor mutations. J. Steroid Biochem. Mol. Biol. 53: 443-448 (1995).
  • Guido Jenster, Petra E. de Ruiter, Hetty A.G.M. van der Korput, George G.J.M. Kuiper, Jan Trapman and Albert O. Brinkmann. Changes in the abundance androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry 33: 14064-14072 (1994).
  • Guido Jenster, Jan Trapman and Albert O. Brinkmann. Nuclear import of the human androgen receptor.. Biochem. J. 293: 761-768 (1993).
  • George G.J.M. Kuiper, Petra E. de Ruiter, Jan Trapman, Guido Jenster and A.O. Brinkmann. In vitro translation of androgen receptor cRNA results in an activated receptor protein. Biochem. J. 296: 161-167 (1993).
  • G. Jenster, J.A.G.M. van der Korput, J. Trapman and A.O. Brinkmann. Functional domains of the human androgen receptor. J. Steroid Biochem. Mol. Biol. 41: 671-675 (1992).
  • A.O. Brinkmann, G. Jenster, G.G.J.M. Kuiper, C. Ris, J.H. van Laar, J.A.G.M. van der Korput, H.J. Degenhart, M.A. Trifiro, L. Pinsky, G. Romalo, H.U. Schweikert, J. Veldscholte, E. Mulder and J. Trapman. The human androgen receptor: structure/function relationship in normal and pathological situations. J. Steroid Biochem. Mol. Biol. 41: 361-368 (1992).
  • J. Veldscholte, C.A. Berrevoets, C. Ris-Stalpers, G.G.J.M. Kuiper, G. Jenster, J. Trapman, A.O. Brinkmann and E. Mulder. The androgen receptor in LNCaP cells contain a mutation in the steroid binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41: 665-669 (1992).
  • Th.H. van der Kwast, N.D. Zegers, G. Jenster, W. Boersma, A.O.Brinkmann and J. Trapman. Multi-assay performance of a monoclonal antibody directed against the human androgen receptor. Progress in Histo- and Cytochemistry vol.26, no.1-4: 61-67 (1992).
  • Nora Heisterkamp, Guido Jenster, Dimitris Kioussis, Paul K. Pattengale and John Groffen. Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Research 1: 45-53 (1991).
  • C. Ris-Stalpers, M.A Trifiro, G.G.J.M. Kuiper, G. Jenster, G. Romalo, T. Sai, H.C.J. van Rooij, M. Kaufman, R.L. Rosenfield, S. Liao, H-U. Schweikert, J. Trapman, L. Pinsky and A.O. Brinkmann. Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone binding characteristics. Mol. Endocrinol. 5: 1562-1569 (1991).
  • Guido Jenster, Hetty A.G.M. van der Korput, Cor van Vroonhoven, Theo H. van der Kwast, Jan Trapman and Albert O. Brinkmann. Domains in the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 5: 1396-1404 (1991).
  • Frank van Leeuwen, Marc J. van de Vijver, Job Lomans, Liesbeth van Deemter, Guido Jenster, Tetsu Akiyama, Tadashi Yamamoto and Roel Nusse. Mutation of the human neu protein facilitates down modulation by monoclonal antibodies. Oncogene 5: 497-503 (1990).
  • Nora Heisterkamp, Guido Jenster, Joanne ten Hoeve, Daniel Zovich, Paul K. Pattengale and John Groffen. Acute leukaemia in bcr/abl transgenic mice. Nature 344: 251-253 (1990).
  • J. Veldscholte, C. Ris-Stalpers, G.G.J.M. Kuiper, G. Jenster, C. Berrevoets, E. Claassen, H.C.J. van Rooij, J. Trapman, A.O. Brinkmann and E. Mulder. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173: 534-540 (1990).